p63 as a prognostic marker for giant cell tumor of bone

Yanagisawa, Michiro; Kakizaki, Hiroshi; Okada, Kyoji; Torigoe, Tomoaki; Kusumi, Tomomi

doi:10.3109/03009734.2012.724731

Cited by 12 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in contrast to their series, all our cases of NOF were negative ( Table 2). In the study of Yanagisawa et al [9] performed on 36 patients, the mean percentage of positive cells was lower than we observed: 36.3 % for GCTB, 15.2 % for CB, 5.8 % for ABC and 3.4 % for NOF. These discrepancies might result from the number of cases studied, the type of antibody used, the type and duration of the decalcification of bone specimens or the differences in cut-off used for assessing p63 immunoreactivity: >10 % for Lee et al [5], >5 % for Dickson et al [4] and >1 % for the present series.…”

Section: Utility Of P63 Ihc For a Diagnosis Of Benign Giant Cell-richcontrasting

confidence: 84%

“…However, even in GCTB, p63 expression is heterogeneous. Recently, Yanagisawa et al reported that the highest scores of p63 expression are found in tumours that recur [9]. Contrary to earlier studies on the diagnostic value of p63 expression in giant-cell rich lesions [4,5], we and others [10,11] found wider expression also in chondroblastoma and ABC, which are the main differential diagnoses.…”

Section: Utility Of P63 Ihc For a Diagnosis Of Benign Giant Cell-richcontrasting

confidence: 79%

“…Nuclear p63 expression has been found in squamous epithelium, urothelium and subpopulations of basal cells in the prostatic, mammary and bronchial glands [7,8]. The diagnostic value of p63 expression in bone pathology, especially in discriminating GCTB from its mimics, has been explored in a few studies on a small number of patients [4,5,9] with less than consistent results. The validation of this marker requires larger series to assess its diagnostic value in daily practice.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained

Paula

Vasiljevic²,

Giorgi

et al. 2014

Virchows Arch

View full text Add to dashboard Cite

Some primary malignant or benign tumours of bone contain numerous multinucleated cells. These "giant cell-rich tumours of bone" have overlapping features and clinical and radiological data are needed to reach an accurate pathological diagnosis. We studied the potential contribution of p63 immunohistochemistry to the reliability of the histological diagnosis. We performed a multicentric retrospective study of 291 giant cell-rich tumours of bone which included 119 giant cell tumours of bone (GCTB), 76 aneurysmal bone cysts (ABC), 49 chondroblastomas (CB), 15 nonossifying fibromas (NOF), 10 giant cell reparative granulomas (RG) of jaws, 1 giant cell lesion of small bones, 2 hyperparathyroidism-related brown tumours (BT), 17 bone sarcomas with numerous osteoclasts and 2 malignant giant cell tumours of bone. p63 is expressed in ABC, CB, NOF, RG, BT and GCTB, but its expression in more than 50 % of mononuclear cells is strongly suggestive of a diagnosis of GCTB. In contrast, malignant GCTB were mostly negative. Our results show that p63 is expressed in a broad range of benign giant cell-rich tumours of bone, consistent with data in the recent literature, while infrequent in malignant tumours. With a cut-off 50 %, the presence of p63 positive cells is useful in supporting a diagnosis of giant cell-rich tumour of bone. However, a final diagnosis cannot be made without due consideration of all clinical/radiological and pathological data.

show abstract

Section: Utility Of P63 Ihc For a Diagnosis Of Benign Giant Cell-richcontrasting

confidence: 84%

Section: Utility Of P63 Ihc For a Diagnosis Of Benign Giant Cell-richcontrasting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained

Paula

Vasiljevic²,

Giorgi

et al. 2014

Virchows Arch

View full text Add to dashboard Cite

show abstract

“…TP63 regulates cell cycle progression in giant cell tumour of bone [26]. Moreover, p63 expression may have prognostic value in giant cell tumour of bone because recurrent tumours showed a higher extent and intensity of p63 expression in comparison with non-recurrent samples [106]. One may speculate that p63 is involved in the biology of lesions with osteoclast-like giant cells irrespective of their cellular origin.…”

Section: Ucogc and Giant Cell Tumour Of The Bonementioning

confidence: 99%

Pan-p63 but not ΔNp63 (p40) expression in undifferentiated carcinoma of the pancreas

Liszka

2020

pjp

View full text Add to dashboard Cite

Undifferentiated carcinoma of the pancreas (UC) is a carcinoma without a definitive direction of differentiation. Tumour protein p63 is a regulator of squamous phenotype, which may also be engaged in tumour development. N-terminal isoforms of p63 are TAp63 and ΔNp63. Pan-p63 antibodies are able to detect both isoforms, whereas p40 antibodies recognise the ΔNp63 isoform only. The aim of the study was to describe pan-p63/p40 immunohistochemical expression patterns in pancreatic neoplasms: UC, ductal adenocarcinomas, neuroendocrine tumours, neuroendocrine carcinomas, serous cystic neoplasms, and solid pseudopapillary neoplasms. DAK-p63 and BC28 antibodies were used for pan-p63 and p40 detection, respectively. Moderate-to-strong pan-p63 was found in anaplastic (pleomorphic giant cell) UC (n = 4), sarcomatoid UC (n = 2), UC with osteoclast-like giant cells (n = 3), and ductal carcinomas with partial squamous differentiation. Weak and focal pan-p63 expression was found in monomorphic UC (n = 3) and in the majority of neuroendocrine carcinomas (6/7 cases). Pan-p63 expression was infrequent in ductal carcinomas without squamous differentiation and in neuroendocrine tumours. Serous cystic and solid pseudopapillary neoplasms were pan-p63-negative. Ductal carcinomas with partial squamous differentiation were the only tumours with evident p40 expression. Pan-p63(+)/p40(-) immunohistochemical status may be supportive for UC diagnosis. The pan-p63 expression was not equivalent to squamous differentiation in pancreatic neoplasia.

show abstract

“…Yanagisawa ve arkadaşla-rının yaptığı bir çalışmada DHT olgularının sadece %36,3'ünde p63'ün pozitif olmasına rağmen cerrahi sonrası nüks olan DHT olgularının %73,6'sında pozitif olması nedeniyle nüks için iyi bir prognostik faktör olabileceği belirtilmiştir. [20] tümördeki dev hücrelerde ve tümörün ossifikasyonunda etkili olmadığı bildirilmiştir. [10] Son yıllarda, DHT'nin stromal hücreleri ve dev hüc-releri arasındaki RANKL ilişkisinin daha iyi anlaşılması sonrasında Amgen tarafından geliştirilen RANKL'ye karşı insan monoklonal antikoru olan denosumabın DHT tedavisinde kullanımı gündeme gelmiştir.…”

Section: Tedavi̇unclassified

Kemiğin dev hücreli tümörü

Deveci¹

2013

TOTBID

View full text Add to dashboard Cite

p63 as a prognostic marker for giant cell tumor of bone

Cited by 12 publications

References 20 publications

A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained

A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained

Pan-p63 but not ΔNp63 (p40) expression in undifferentiated carcinoma of the pancreas

Kemiğin dev hücreli tümörü

Contact Info

Product

Resources

About